Mylan launches review to unlock firm’s“true value”

Mylan has put together a board committee which is “actively evaluating a wide range of alternatives to unlock the true value of our one-of-a-kind platform”. Describing current “negative trends and dynamics” in the US as “unsustainable for the US healthcare system”, Mylan insisted investors “under-appreciate and under-value the durability, differentiation and strengths of Mylan’s global diversified business”.